JAK2 and myeloproliferative neoplasm: The tolerability of this pan-inhibitor in the preclinical studies led to the establishment of a phase Ib clinical trial evaluating the combination of a JAK2 specific inhibitor (TG101209) with panobinostat in MPN patients [20].